文献速递免疫规划传染病防控与疫情报告

PCV13对北京市儿童全因住院肺炎的保护效果:真实世界证据

Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence.
PubMed 文献 · Vaccine · 2024-04-08

研究基于北京市2017年出生儿童的预防接种记录和住院病历数据库,按年龄、性别和区县1:4匹配纳入接种与未接种PCV13的儿童,比较出生后12、18、24和30个月内的全因住院肺炎发病率、疫苗效果(VE)和直接医疗费用。结果显示接种组四个时点发病率均低于未接种组,12、18、24个月时差异有统计学意义,VE随时间递减,30个月时几乎消失。

要点

  • 接种组12、18、24个月全因住院肺炎发病率显著低于未接种组。
  • 12个月内VE最高为41.9%(95%CI 19.6%,58.0%),随观察时间延长下降。
  • 4剂次接种18个月和24个月内VE分别为39.9%和27.2%。

核心结论

  • PCV13对全因住院肺炎有一定保护效果,加强免疫策略保护效果最佳,对纳入免疫规划具有重大公共卫生意义。

研究设计与样本

  • 基于北京市预防接种记录和住院病历数据库,选取2017年出生儿童,按年龄、性别和区县1:4匹配接种与未接种PCV13组,比较出生后12、18、24和30个月同期的全因住院肺炎发病率、VE和直接医疗费用。

主要发现

  • 接种组较未接种组全因住院肺炎发病率在12个月(0.42% vs 0.72%,P=0.001)、18个月(0.90% vs 1.26%,P=0.002)和24个月(1.37% vs 1.65%,P=0.046)显著降低。
  • 12个月内VE最高为41.9%(95%CI 19.6%,58.0%),18个月内为29.3%(95%CI 11.4%,43.5%),24个月内为17.1%(95%CI 0.3%,31.1%),30个月内几乎消失。
  • 4剂次接种18个月内VE为39.9%(95%CI 20.3%,54.7%),24个月内为27.2%(95%CI 8.6%,42.0%)。
  • 接种组住院费用中位数在四个时点均高于未接种组,但无统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The study evaluated the protective effect of 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) against all-cause hospitalized pneumonia in children in Beijing. METHODS: Based on the vaccination record and inpatient medical record database of Beijing, children born in 2017 in Beijing, matched by age, gender, and district of the children with the ratio of 1:4, were selected as the vaccinated and unvaccinated groups according whether if vaccinated with PCV13. The incidence rate and 95 % confidence interval (95 %CI), vaccine effectiveness (VE) and direct medical costs of all-cause hospitalized pneumonia were calculated and compared within the same period of 12 months, 18 months, 24 months and 30 months after the birth of the child. RESULTS: The decreased incidence rates of all-cause hospitalized pneumonia were observed at the four points in the PCV13 vaccinated group compared to the unvaccinated group, which were significant at the points of 12 months (0.42 % vs. 0.72 %, P = 0.001), 18 months (0.90 % vs. 1.26 %, P = 0.002) and 24 months (1.37 % vs. 1.65 %, P = 0.046). The VE of PCV13 against all-cause hospitalized pneumonia within 12 months was the highest as 41.9 % (95 % CI 19.6 %, 58.0 %), followed by 29.3 % (95 % CI 11.4 %, 43.5 %) within 18 months, 17.1 % (95 % CI 0.3 %, 31.1 %) within 24 months and it almost disappeared within 30 months. The VE of 4-dose vaccination within 18 months and 24 months were 39.9 % (95 % CI 20.3 %, 54.7 %) and 27.2 % (95 % CI 8.6 %, 42.0 %), respectively. The median hospitalization cost of the children in the vaccinated group was higher at the four points but without significance. CONCLUSIONS: PCV13 had a certain protective effect on all-cause hospitalized pneumonia, and the booster immunization strategy had the best protective effect with great public health significance to enter the immunization program.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lv M, Du J, Xie MZ, et al. Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence. Vaccine. 2024. PMID: 38594120. doi:10.1016/j.vaccine.2024.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。